HpVac is a privately owned company.

HpVac is focused on the development of HpVac-R13 as a preventive and therapeutic first-line therapy against asthma, eczema, food allergies and related allergic diseases, as well as inflammatory bowel conditions such as Crohn's disease and ulcerative colitis. 

HpVac holds an exclusive, world-wide licence from the University of Zurich. 


Jacques Billy
Jacques Billy, Msc
Member of the Board
Chief Financial Officer at GBC SA
Christine Serratrice
Dr. Christine Serratrice
Chief Medical Officer at GBC SA
Jeffrey Shaw
Dr. Jeffrey Shaw
Member of the Board
Chief Executive Officer at GBC SA